Jazz Pharmaceuticals raises 2026 revenue guidance to $4.78 billion-$4.85 billion
JAZZ•Jazz Pharmaceuticals raised its 2026 revenue forecast to $4.78 billion-$4.85 billion from $4.6 billion-$4.75 billion. Third-quarter revenue rose 10% to $1.24 billion.
1. Guidance raised
Jazz Pharmaceuticals raised its 2026 revenue forecast to $4.78 billion-$4.85 billion from $4.6 billion-$4.75 billion. It increased adjusted gross margin guidance to 90.5%-91.5% from 90%-91%, while raising its adjusted effective tax rate forecast to 19.5%-21.5% from 11.5%-13.5%, reflecting non-tax-deductible acquired research charges from the Actio acquisition.
2. Revenue outlook
Third-quarter revenue rose 10% to $1.24 billion, driven by oncology and Xywav growth. The company expects rare sleep revenue of $2.13 billion-$2.18 billion and projects Xywav growth in the low double digits to low teens.
